title: Will BMY's Growth Portfolio Drive Third-Quarter Results?
source: Yahoo
date: 2025-10-21
url: https://finnhub.io/api/news?id=413d9b2081ab4cb54c5c4624de3ca641162dae59775f9933fd67df893d491a31
Bristol Myers leans on new drugs like Opdivo and Reblozyl to offset pressure from generics as its Growth Portfolio drives stability.
